HK Stock Market Move | HELENS (09869) rose more than 12% and the board of directors decided to exercise the share buyback authorization.
Helen Group (09869) rose by more than 12%, as of the time of writing, it increased by 12.37% to 1.09 Hong Kong dollars, with a trading volume of 2.0072 million Hong Kong dollars.
HELENS(09869) rose more than 12%, as of the deadline, up 12.37% to 1.09 Hong Kong dollars, with a turnover of 20.72 million Hong Kong dollars.
On the news front, HELENS announced that shareholders had approved a general and unconditional authorization for directors to repurchase up to 10% of the total number of issued shares on the day of the annual general meeting (up to 127 million shares). The company announced that on November 6, 2025, the board of directors decided to exercise the share repurchase authorization, intending to repurchase a number of shares not exceeding the authorization limit using existing internal financial resources in the open market. The company believes that the current trading price of the shares does not fully reflect the company's intrinsic value. Share repurchases reflect the company's long-term confidence in its business growth prospects and financial condition, enhancing the net asset value and earnings return per share, and are in the best interests of the company and shareholders.
Related Articles

SHINEWAY PHARM (02877) had a revenue of 2.415 billion RMB in the first three quarters, a decrease of 16.3% year-on-year.

FIRST PACIFIC (00142) has completed the proposed demerger of MAYNILAD WATER SERVICES, INC. and will independently list on the Philippine Stock Exchange.

BOAN BIOTECH (06955): Two types of Dexu Monoclonal Antibody Injections have been accepted for market approval in the United Kingdom.
SHINEWAY PHARM (02877) had a revenue of 2.415 billion RMB in the first three quarters, a decrease of 16.3% year-on-year.

FIRST PACIFIC (00142) has completed the proposed demerger of MAYNILAD WATER SERVICES, INC. and will independently list on the Philippine Stock Exchange.

BOAN BIOTECH (06955): Two types of Dexu Monoclonal Antibody Injections have been accepted for market approval in the United Kingdom.

RECOMMEND

SERES Faces Market Test in Hong Kong: Shares Open Below Issue Price Despite HK$220 Billion Market Valuation
06/11/2025

Copper Prices Surge While Former “Copper King” Who Outpaced Huawei and Tencent Falls into Decline
06/11/2025

National Energy Administration Reports New-Type Energy Storage Capacity Exceeds 100 Million Kilowatts by End‑September
06/11/2025


